Immune checkpoint inhibitors (ICIs) have revolutionized the landscape of therapeutic
options for many cancers. These treatments have demonstrated improved efficacy and often …

Over the past decade, the emergence of effective immunotherapies has revolutionized the
clinical management of many types of cancers. However, long-term durable tumour control …

Background In an early-phase study involving patients with advanced non–small-cell lung
cancer (NSCLC), the response rate was better with nivolumab plus ipilimumab than with …

Importance Currently, predictive biomarkers for response to immune checkpoint inhibitor
(ICI) therapy in lung cancer are limited. Identifying such biomarkers would be useful to refine …

Lung cancer is the most often diagnosed cancer in the world and the most frequent cause of
cancer death. The prognosis for lung cancer is relatively poor and 75% of patients are …

Importance Tumor mutational burden (TMB) is a potential biomarker associated with
response to immune checkpoint inhibitor therapies. The prognostic value associated with …

Triggering receptor expressed on myeloid cells-2 (TREM2) is a transmembrane receptor of
the immunoglobulin superfamily and a crucial signaling hub for multiple pathological …

Molecular heterogeneity is a frequent event in cancer responsible of several critical issues in
diagnosis and treatment of oncologic patients. Lung tumours are characterized by high …

The recent advent of immunomodulatory therapies into the clinic has demanded the
identification of innovative predictive biomarkers to identify patients most likely to respond to …

Background: Melanoma is highly immunogenic and therefore suitable for immunotherapy,
but the efficacy is limited by response rate. In several types of tumor, tumor mutation burden …